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We illustrate the potential for highly misleading results attribut-
able to inclusion of immortal person-time using a hypothetic study of
5-year survival after treatment initiation among patients diagnosed at
a single clinical center. Suppose investigators prospectively enrolled
350 patients per year for 2 years and observed these patients for 5 years.
To bolster sample size, investigators augmented these prospective data
with prevalent cases identified retrospectively in the center’s registry of
current patients. Imagine that they included 350 patients per year for
the 5 years before study onset. For each patient with cancer, the
investigators knew the number of years from treatment initiation to
study enrollment (if any), the number of years from treatment initia-
tion to death, and whether the patient was identified prospectively
or retrospectively.
Suppose the 1,750 prospectively enrolled patients with cancer
contributed 3,473 person-years at risk for death, during which 111
deaths occurred, yielding a rate of 3.2 deaths per 100 person-years. In
addition, 1,750 retrospectively enrolled patients with cancer contrib-
uted 8,506 person-years between treatment initiation and end of
study; 4,169 person-years (49%) were accrued after study enrollment,
during which 136 deaths occurred. Note that retrospectively en-
rolled patients had to be current patients at the time the study
began, so they had to have survived from diagnosis to study incep-
tion. Counting all person-time, both mortal and immortal, among
retrospectively enrolled patients would yield an overall rate of 1.6
deaths per 100 person-years, which is approximately half the pro-
spectively measured rate. However, counting only mortal person-
time among retrospectively enrolled patients would yield the
correct rate of 3.3 deaths per 100 person-years.
In a given study, immortal person-time usually accrues between
the first event required for study entry (eg, cancer diagnosis or incep-
tion of treatment) and the last event required for study entry (eg,
provision of written informed consent or collection of a biologic
specimen). Immortal person-time may also arise when a list of poten-
tial study patients is used to define a cohort, but the list is modified
between the time of its creation and the time it reaches the hands of
investigators. For example, if study patients were removed from a
registry because of death or emigration, then the registry list would
only include survivors at the time it reached investigators. For the
survivors on the list, the time between their entry into the registry and
delivery of the list to investigators would be immortal person-time.
Accrual of person-time from the date of the last study or
exposure-defining criterion thus provides a simple solution for avoid-
ing immortal and immune person-time bias when estimating out-
come rates, rate differences, and rate ratios. Allowing patients into risk
sets only when person-time is not immortal or immune using meth-
ods for late entry6,7 or time-varying exposure8 provides the analogous
solution when estimating survival curves or hazard ratios. This solu-
tion of restricting or reallocating counted person-time is not fool-
proof. Analogous to informative censoring, bias will persist if the
timing of late entry is informative with respect to the outcome of
interest, conditional on measured variables.9 In addition, this solution
is not optimal if a study samples exposed and unexposed patients
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TO THE EDITOR: Immortal person-time arises in an observational 
study when follow-up time is included in person-time at risk for the 
study outcome, even though that time precedes the last event required 
for entry into the study population or satisfaction of an exposure 
definition.1,2 Immune person-time is similar, but it pertains to out-
comes other than death. If a study patient were to have incurred the 
outcome or been censored during immortal or immune person-time, 
then the patient would not have satisfied the requirements for inclu-
sion in the study or exposure category. A study or exposure category 
that includes immortal or immune person-time yields a downwardly 
biased outcome rate and an upwardly biased survival curve. This bias 
occurs because the accumulated person-time exceeds person-time 
actually at risk. When comparing rates or survival curves among 
exposure categories, the net effect of immortal or immune person-
time bias may be in any direction.
Examples of research studies affected by immortal or immune 
person-time appear with some regularity in clinical epidemiology, 
including in Journal of Clinical Oncology. Consider, for example, a 
study of genetic determinants of cancer outcomes among patients 
with cancer. If genotyping is conducted on blood drawn from patients 
after diagnosis, then person-time between diagnosis and drawing of 
blood is immortal. Patients who do not survive to give blood cannot be 
included in the study. The immortal person-time between diagnosis 
and drawing of blood should not be included in outcome rates or 
survival analysis. Articles by Lim et al3 and Kiyotani et al,4 who re-
ported studies of modification of tamoxifen effectiveness by CYP2D6 
genotype in metastatic and adjuvant settings, respectively, are pub-
lished examples in which immortal person-time was included in out-
come rates.
Nonrandomized studies of adherence to protocols are also often 
susceptible to immortal person-time bias. For example, in a study of 
the association between delayed initiation of radiation therapy and 
breast cancer recurrence,5 person-time was accrued in exposure cate-
gories defined by time from breast-conserving surgery to initiation of 
radiation therapy. No woman for whom adjuvant radiation therapy 
was initiated would have had a recurrence between her diagnosis and 
start of radiation therapy. Time between breast-conserving surgery 
and initiation of radiation therapy therefore resulted in immortal or 
immune person-time and should have been excluded from the follow-
up period.
To diagnose the presence of immortal or immune person-time, 
one can ask: “From the perspective of the study, is the patient at risk for 
the outcome of interest (or any censoring events) at this exposure level 
in all of the contributed person-time?” If the answer is yes, then the 
person-time is mortal and nonimmune and therefore should be 
counted at that exposure level. But if the answer is no, then at least a 
portion of the person-time is either immortal or immune, and steps 
should be taken to account for the immortal or immune person-time.
differentially from the underlying population.10 Immortal and im-
mune person-time can thus be a subtle bias to diagnose, but it can also
be as treacherous as it is subtle, and therefore it must be treated rather
than overlooked.
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